Australia's COVID-19 vaccine program continues to evolve with the recent approval of updated vaccines targeting newer variants, such as the Omicron JN.1 subvariant. These updated vaccines, including options from Pfizer and Moderna, are designed to provide stronger protection against severe illness and hospitalisation. The Australian Technical Advisory Group on Immunisation (ATAGI) recommends these vaccines as booster doses for individuals at higher risk, such as those over 65, people with chronic health conditions, and healthcare workers. This rollout coincides with an anticipated rise in cases during the holiday season. 

Boosters aim to address waning immunity and adapt to the virus's evolving nature, ensuring that vulnerable populations remain protected. Vaccination remains a key strategy for minimising the health and societal impacts of COVID-19, especially as new variants like XBB and Eris spread. Access to these vaccines is critical, and Australians are encouraged to consult healthcare providers for guidance on eligibility and timing.